Pfizer reported on Tuesday positive results from the Phase III clinical trial of its vaccine against RSV lower respiratory tract infections in young adults.

According to the company, these data showed neutralizing antibody levels no lower than those obtained in the successful Phase III study conducted in over 34,000 people aged over 60.

Two months after vaccine administration, patients aged between 18 and 59 had antibody levels at least four times higher than before vaccination, Pfizer adds.

The pharmaceutical group, which adds that its product was well tolerated, notes that no vaccine currently exists for the prevention of respiratory tract infections caused by RSV in adults aged 18 to 59, despite the fact that 9.5% of them suffer from a chronic disease making them vulnerable to these complications.

Copyright (c) 2024 All rights reserved.